• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Relmada Therapeutics Inc (NQ: RLMD )

    2.600 +0.010 (+0.39%)
    Streaming Delayed Price Updated: 2:06 PM EDT, Aug 29, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 8,082
    Open 2.640
    Bid (Size) 2.600 (5)
    Ask (Size) 2.660 (1)
    Prev. Close 2.590
    Today's Range 2.560 - 2.660
    52wk Range 1.880 - 7.223
    Shares Outstanding 17,472,986
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    RLMD Stock Earnings: Relmada Therapeutics Beats EPS for Q2 2024
    RLMD stock results show that Relmada Therapeutics beat analyst estimates for earnings per share the second quarter of 2024. 
    Via InvestorPlace
    Keurig Dr Pepper To Rally Around 18%? Here Are 10 Top Analyst Forecasts For Wednesday
    Via Benzinga

    Performance

    YTD
    -40.50%
    -40.50%
    1 Month
    -34.67%
    -34.67%
    3 Month
    -11.26%
    -11.26%
    6 Month
    -57.65%
    -57.65%
    1 Year
    -22.16%
    -22.16%

    More News

    Read More
    7 Penny Biotech Stocks to Triple Your Investment
    Via InvestorPlace
    RLMD Stock Earnings: Relmada Therapeutics Beats EPS for Q1 2024
    Via InvestorPlace
    RLMD Stock Earnings: Relmada Therapeutics Misses EPS for Q4 2023
    Via InvestorPlace
    Recap: Relmada Therapeutics Q4 Earnings
    Via Benzinga
    Earnings Outlook For Relmada Therapeutics
    Via Benzinga
    Earnings Outlook For Relmada Therapeutics
    Via Benzinga
    Earnings Scheduled For March 19, 2024
    Via Benzinga
    Relmada Therapeutics And 2 Other Penny Stocks Insiders Are Buying
    Via Benzinga
    Topics Stocks
    Exposures US Equities
    Why Mobileye Global Shares Are Trading Lower By Over 23%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
    Via Benzinga
    12 Health Care Stocks Moving In Thursday's Intraday Session
    Via Benzinga
    Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
    Via InvestorPlace
    12 Health Care Stocks Moving In Thursday's Pre-Market Session
    Via Benzinga
    Relmada Therapeutics' Lead Candidate Shows Promise In Pivotal Depression Study
    Via Benzinga
    Bragar Eagel & Squire, P.C. Is Investigating Shift4, Waldencast, Relmada, and DoubleVerify and Encourages Investors to Contact the Firm
    From Bragar Eagel & Squire
    Via GlobeNewswire
    FDA's Rejection of Sage/Biogen's Zuranolone Boosts Prospects for Axsome's Auvelity, Analyst Says
    Via Benzinga
    Bragar Eagel & Squire, P.C. Is Investigating Shift4, Waldencast, Relmada, and DoubleVerify and Encourages Investors to Contact the Firm
    From Bragar Eagel & Squire
    Via GlobeNewswire
    7 Healthcare Stocks to Ditch Before They Make Your Portfolio Sick
    Via InvestorPlace
    Bragar Eagel & Squire, P.C. Is Investigating Relmada, Arrival, FMC, and Viasat and Encourages Investors to Contact the Firm
    From Bragar Eagel & Squire
    Via GlobeNewswire
    Bragar Eagel & Squire, P.C. Is Investigating Waldencast, Relmada, DoubleVerify, and Castle and Encourages Investors to Contact the Firm
    From Bragar Eagel & Squire
    Via GlobeNewswire
    Bragar Eagel & Squire, P.C. Is Investigating Shift4, Waldencast, Relmada, and DoubleVerify and Encourages Investors to Contact the Firm
    From Bragar Eagel & Squire
    Via GlobeNewswire
    Bragar Eagel & Squire, P.C. Is Investigating Shift4, Waldencast, Chegg, and Relmada and Encourages Investors to Contact the Firm
    From Bragar Eagel & Squire
    Via GlobeNewswire
    Bragar Eagel & Squire, P.C. Is Investigating Shift4, Waldencast, Chegg, and Relmada and Encourages Investors to Contact the Firm
    From Bragar Eagel & Squire
    Via GlobeNewswire
    Bragar Eagel & Squire, P.C. Is Investigating Seagate, Chegg, Relmada, and DoubleVerify and Encourages Investors to Contact the Firm
    From Bragar Eagel & Squire
    Via GlobeNewswire
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.